Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Recker RR, et al. Among authors: mesenbrink p. J Bone Miner Res. 2008 Jan;23(1):6-16. doi: 10.1359/jbmr.070906. J Bone Miner Res. 2008. PMID: 17892374 Free article. Clinical Trial.
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial. Eastell R, et al. Among authors: mesenbrink p. J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30. J Clin Endocrinol Metab. 2009. PMID: 19567517 Free PMC article.
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial. Eastell R, et al. Among authors: mesenbrink p. Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3. Osteoporos Int. 2010. PMID: 19802508 Free PMC article. Clinical Trial.
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Orwoll ES, et al. Among authors: mesenbrink p. J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119. J Bone Miner Res. 2010. PMID: 20499357 Free article. Clinical Trial.
Effects of antiresorptive treatment on nonvertebral fracture outcomes.
Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR. Mackey DC, et al. Among authors: mesenbrink p. J Bone Miner Res. 2011 Oct;26(10):2411-8. doi: 10.1002/jbmr.446. J Bone Miner Res. 2011. PMID: 21710615 Free article.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Black DM, et al. Among authors: mesenbrink p. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312. N Engl J Med. 2007. PMID: 17476007 Free article. Clinical Trial.
47 results